Point of Care Nano-Technology Inc

Point of Care Nano-Technology, Inc. (OTC: PCNT) is a Nevada corporation headquartered in Whitehouse Station, New Jersey, engaged in the development and commercialization of diagnostic test kits designed to detect illnesses through the testing of human saliva. The company's lead product platform, the EZ Saliva test kits, is built on the principle that human saliva contains biomarkers — proteins, nucleic acids, and other biological molecules — that can be analyzed to identify the presence of specific pathogens, antibodies, or disease markers without requiring blood draws or other more invasive sample collection methods. Saliva-based diagnostics represent a distinct approach to point-of-care testing that prioritizes ease of sample collection, patient comfort, and suitability for self-administered testing scenarios where trained phlebotomists are not available.<br><br>The development of non-invasive or minimally invasive diagnostic technologies has been a significant area of innovation in the in vitro diagnostics industry, driven by patient preference for less painful and more convenient testing, the potential for higher rates of patient compliance with recommended diagnostic testing protocols, and the operational advantages of testing programs that do not require clinical facilities or trained blood draw staff. Saliva contains many of the same diagnostic analytes found in blood serum, though typically at lower concentrations, creating technical challenges that Point of Care Nano-Technology has sought to address through the nano-scale sensor technologies that give the company its name. The EZ Saliva platform applies these sensing technologies to achieve clinically meaningful sensitivity for illness detection using only a saliva sample.<br><br>Point of Care Nano-Technology, Inc. has a class of securities registered with the Securities and Exchange Commission under Exchange Act Section 12(g) and files periodic reports including annual Form 10-K filings. The company's common stock trades on the OTC Markets under the Expert Market tier under the ticker symbol PCNT. The company has acknowledged material weaknesses in its internal controls over financial reporting, a risk factor common among early-stage development companies that are building out their financial operations and administrative infrastructure. As the company works toward commercialization of its EZ Saliva diagnostic platform, it participates in the point-of-care diagnostics sector, which has seen significant growth in demand for rapid, simple, and non-invasive illness detection solutions.